Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Non-Current Assets (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Non-Current Assets readings, the most recent being $435052.6 for Q4 2022.

  • On a quarterly basis, Non-Current Assets fell 25.46% to $435052.6 in Q4 2022 year-over-year; TTM through Dec 2022 was $2.0 million, a 25.3% decrease, with the full-year FY2022 number at $435052.6, down 25.46% from a year prior.
  • Non-Current Assets hit $435052.6 in Q4 2022 for Cardiol Therapeutics, down from $460618.2 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $723519.7 in Q4 2020 to a low of $435052.6 in Q4 2022.
  • Median Non-Current Assets over the past 3 years was $567206.1 (2021), compared with a mean of $570919.5.
  • Biggest five-year swings in Non-Current Assets: decreased 19.33% in 2021 and later dropped 26.73% in 2022.
  • Cardiol Therapeutics' Non-Current Assets stood at $723519.7 in 2020, then decreased by 19.33% to $583688.3 in 2021, then dropped by 25.46% to $435052.6 in 2022.
  • The last three reported values for Non-Current Assets were $435052.6 (Q4 2022), $460618.2 (Q3 2022), and $506629.9 (Q2 2022) per Business Quant data.